Status:
COMPLETED
Replication of the D58 Asthma Trial in Healthcare Claims Data
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Asthma
Eligibility:
All Genders
12-120 years
Brief Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of cl...
Detailed Description
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to re...
Eligibility Criteria
Inclusion
- Criteria:
- Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.
- Eligible cohort entry dates:
- Budesonide-formoterol was approved by FDA on July 21, 2006 for management of asthma. The initial eligible cohort entry date was the first date after July 21, 2006 for both the databases investigated (IBM MarketScan, Optum CDM). The last date eligible as cohort entry date was the end of available data for IBM MarketScan and Optum CDM. The following eligible cohort entry dates were included:
- IBM MarketScan: July 21, 2006 - December 31, 2018 (end of available data)
- Optum CDM: July 21, 2006 - June 30, 2020 (end of available data)
- ≥12 years of age
- Documented clinical diagnosis of asthma for ≥1 year prior to randomization
- History of at least one asthma exacerbation in the previous year (but none in the 4 weeks prior to randomization. An asthma exacerbation was defined as an event requiring treatment with systemic corticosteroids or requiring hospitalization (i.e. an inpatient stay or \>24-hour stay in the observation area of an emergency room or local equivalent)
- Receiving either:
- A stable dose of ICS alone or in combination with a LABA, leukotriene receptor antagonist or other maintenance therapy/therapies for ≥4 weeks prior to randomization (any patient maintained on a stable high-dose ICS with or without a LABA or LTRA or other maintenance therapy/therapies was required to have an ACQ6 total score of \<1.5 at screening) OR
- A stable dose of LTRA or xanthine monotherapy (for ≥4 weeks prior to randomization) or daily SABA (in the 4 weeks before randomization but ≤8 puffs a day on two consecutive days, or ≥25 puffs in one day, in the 7 days prior to screening). Patients on LTRAs, xanthines, or daily SABA, were eligible only if they recorded an ACQ6 total score of ≥1.5, and in the investigator's clinical judgment, the patient's asthma severity could have justified treatment with ICS or ICS/LABA combination
Exclusion
- A history of life-threatening asthma (defined as an asthma episode that required intubation and/or was associated with hypercapnia requiring non-invasive ventilatory support)
- One of the following:
- Any asthma exacerbation requiring systemic corticosteroids within 4 weeks prior to randomization OR
- \>4 separate exacerbations OR
- \>2 hospitalizations (an inpatient stay or \>24- hour stay in the observation area of an emergency room or local equivalent) due to asthma in the previous year
- Received systemic corticosteroids for any reason in the 4 weeks prior to randomization
- Had an ongoing asthma exacerbation requiring systemic corticosteroids
- Concurrent respiratory disease (chronic obstructive pulmonary disease, chronic bronchitis, emphysema, idiopathic pulmonary fibrosis, bronchiectasis, and/or any pulmonary disease)
- A smoking history of \>10 pack-years
- Respiratory infection or other viral/bacterial illness
- Pregnancy (current/planned) and lactation
- Malignancy (with the exception of basal cell carcinoma) within the 5 years prior to study commencement
- Omalizumab or any other monoclonal/polyclonal antibody use in the 6 months prior to randomization
- Concomitant β-blocker use
- Drug/alcohol abuse
Key Trial Info
Start Date :
October 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 11 2021
Estimated Enrollment :
66581 Patients enrolled
Trial Details
Trial ID
NCT04892732
Start Date
October 29 2020
End Date
June 11 2021
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02120